Epstein-Barr virus-encoded small RNA 1 (EBER1) (EBER1)

Epstein-Barr virus-encoded small RNA 1 (EBER1) is a highly abundant, non-polyadenylated viral non-coding RNA expressed during the latent phase of Epstein-Barr virus (EBV) infection. While discovered decades ago, its primary biological function was recently identified as a master regulator of B cell egress from lymphoid tissues and their subsequent dissemination into the peripheral circulation, a process essential for the establishment of life-long viral latency and systemic spread. EBER1 exerts its effects by interacting with host proteins, most notably the ribosomal protein L22 (RPL22) and the lupus-associated antigen (La), which triggers metabolic reprogramming and the evasion of host immune surveillance. This dissemination mechanism is a critical driver in the pathogenesis of EBV-associated malignancies, such as Burkitt lymphoma and nasopharyngeal carcinoma, as well as autoimmune conditions like multiple sclerosis. As a therapeutic target, EBER1 is being investigated for intervention using antisense oligonucleotides and small molecules designed to disrupt its RNA-protein interactions or induce its degradation. Inhibiting EBER1 effectively sequesters infected B cells within lymph nodes, potentially preventing the systemic spread and chronic inflammatory pathology associated with EBV-related diseases.

Other names

EBER1Epstein-Barr virus-encoded small RNA 1Epstein-Barr virus encoded RNA 1EBER-1EBV-encoded small RNA 1TMER4 homolog

Targeted inhibition or degradation of the EBER1 non-coding RNA disrupts its interaction with host factors like RPL22 and La, thereby blocking the metabolic and migratory signaling required for the egress of infected B cells from lymph nodes and their systemic dissemination.